Drugs / CCT3833
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT02437227 | Apr 2015 → Dec 2017 | cancer, melanoma | Royal Marsden NHS Foundation Trust | Completed | No outcome recorded |
News releases announcing trial results or a regulatory action · 1
| Date | Issuer | Release |
|---|---|---|
| 2016-04-21 | Basilea Pharmaceutica | Results Basilea reports presentation of data on clinical oncology programs BAL101553 and BAL3833 at AACR meeting basilea.com ↗
PanRAF/SRC kinase inhibitor BAL3833 inhibits tumor growth in preclinical KRAS-driven cancer models |
All press releases naming this drug 1 release
| Date | Issuer | Release |
|---|---|---|
| 2016-04-21 | Basilea Pharmaceutica | Basilea reports presentation of data on clinical oncology programs BAL101553 and BAL3833 at AACR meeting basilea.com ↗ |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | CCT3833 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02437227 ↗ |
| Known as | BAL-3833 | ChEMBL registry synonym — accepted as the source's own label CHEMBL5831360 ↗ |
| Action | Inhibit | “panRAF inhibitor” NCT02437227 ↗ |
| Modality | Small molecule | — CHEMBL5831360 ↗ |
| Route | Oral | “given orally” NCT02437227 ↗ |